TamaFlex
TamaFlex, licence 80090764: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- GNC Canada Holdings ULC
- NPN or DIN-HM
- 80090764
- Status
- Inactive licence
- Licence date
- 20 February 2019
- Revision date
- 31 May 2022
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Curcuma longa Source : Rhizome Extract : Matériel brut sec Extraction ratio : 7-12:1.0 Dry plant equivalent : 262.5-450 mg Potency : 15.0 % Curcuminoids | 37.5 mg | Not calculated |
| Tamarindus indica Source : Semence(s) Extract : Matériel brut sec Extraction ratio : 8-12:1.0 Dry plant equivalent : 600-900 mg Potency : 90.0 % Proanthocyanidins | 75.0 mg | Not calculated |
Non-medicinal ingredients
Silicate de calcium, Stéarate de magnésium, Cellulose microcristalline, Hypromellose, Phosphate dicalcique, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 1.0 Capsule | 2.0 Jour(s) |
Uses authorised in Canada
Helps to improve joint health by reducing knee joint pain, knee joint stiffness and improving physical function associated with daily physical activity. Helps to reduce/relieve knee joint pain associated with daily physical activity. Helps to reduce knee stiffness associated with daily physical activity. Helps to promote joint comfort associated with daily physical activities. Helps to promote joint movement and physical functioning associated with daily physical activity by reducing joint pain and stiffness. Helps to improve ability to perform daily activities by reducing joint stiffness. Helps relieve joint pain associated with daily physical activity in 14 days. Source of antioxidant(s)/Provides antioxidant(s). Source of antioxidant(s)/Provides antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Provides antioxidants for the maintenance of good health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80090764
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Has the product changed? Photograph the packaging.